2fle: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 12: | Line 12: | ||
===Structural analysis of asymmetric inhibitor bound to the HIV-1 Protease V82A mutant=== | ===Structural analysis of asymmetric inhibitor bound to the HIV-1 Protease V82A mutant=== | ||
<!-- | |||
The line below this paragraph, {{ABSTRACT_PUBMED_18215016}}, adds the Publication Abstract to the page | |||
(as it appears on PubMed at http://www.pubmed.gov), where 18215016 is the PubMed ID number. | |||
--> | |||
{{ABSTRACT_PUBMED_18215016}} | |||
==About this Structure== | ==About this Structure== | ||
2FLE is a 2 chains structure | 2FLE is a 2 chains structure with sequences from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2FLE OCA]. | ||
==Reference== | |||
<ref group="xtra">PMID:18215016</ref><references group="xtra"/> | |||
[[Category: Human immunodeficiency virus 1]] | [[Category: Human immunodeficiency virus 1]] | ||
[[Category: Clemente, J C.]] | [[Category: Clemente, J C.]] | ||
Line 21: | Line 30: | ||
[[Category: Sussman, F.]] | [[Category: Sussman, F.]] | ||
[[Category: Hiv-1 protease]] | [[Category: Hiv-1 protease]] | ||
[[Category: Hydrolase-hydrolase inhibitor complex]] | |||
[[Category: Induced fit]] | [[Category: Induced fit]] | ||
[[Category: Inhibitor]] | [[Category: Inhibitor]] | ||
[[Category: Resistance]] | [[Category: Resistance]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Mar 24 08:24:31 2010'' |
Revision as of 09:24, 24 March 2010
Structural analysis of asymmetric inhibitor bound to the HIV-1 Protease V82A mutantStructural analysis of asymmetric inhibitor bound to the HIV-1 Protease V82A mutant
Template:ABSTRACT PUBMED 18215016
About this StructureAbout this Structure
2FLE is a 2 chains structure with sequences from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.
ReferenceReference
- ↑ Clemente JC, Robbins A, Grana P, Paleo MR, Correa JF, Villaverde MC, Sardina FJ, Govindasamy L, Agbandje-McKenna M, McKenna R, Dunn BM, Sussman F. Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation. J Med Chem. 2008 Feb 28;51(4):852-60. Epub 2008 Jan 24. PMID:18215016 doi:10.1021/jm701170f
Page seeded by OCA on Wed Mar 24 08:24:31 2010